Share to: share facebook share twitter share wa share telegram print page

Divi's Laboratories

Divi's Laboratories Limited
FormerlyDivi's Research Centre
Company typePublic
ISININE361B01024
IndustryPharmaceuticals
Founded12 October 1990 (34 years ago) (1990-10-12)
HeadquartersDivi Towers, Cyber Hills, Gachibowli,
Hyderabad, Telangana
,
India
Key people
  • Murali Krishna Prasad Divi (MD)
  • Satchandra Kiran Divi (CEO)
ProductsActive Pharmaceutical Ingredients
Nutraceuticals
ServicesCustom synthesis
RevenueIncrease ₹9,073 crore (US$1.1 billion) [1] (2022)
Increase ₹3,683 crore (US$440 million) [1] (2022)
Increase ₹2,960 crore (US$350 million) [1] (2022)
Total assetsIncrease ₹13,374 crore (US$1.6 billion) [1] (2022)
Total equityIncrease ₹11,728 crore (US$1.4 billion) [1] (2022)
Owner
  • Divi Satchandra Kiran (20.34%)
  • Nilima Motaparti (20.34%)
  • Divi Swarna Latha (5.27%)
  • Divis Biotech Private Limited (3.01%)
  • Murali Krishna Prasad Divi (2.85%)
Number of employees
13,884 (2020)
Subsidiaries
  • Divis Laboratories (USA) Inc
  • Divi’s Laboratories Europe AG
  • Divi’s Nutraceuticals
Websitedivislabs.com
Footnotes / references
[1][2][3][4]

Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients (APIs) and intermediates, headquartered in Hyderabad.[5][6][2][7] The company manufactures and custom synthesizes generic APIs, intermediates.[8][9] The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals.[10] Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.[11]

In October 2024, Divi and his family were ranked 29th on Forbes list of India’s 100 richest tycoons, with a net worth of $9.2 billion.[12]

History

The company initially started developing commercial processes for the manufacturing of APIs and intermediates. Divi's Research Centre changed its name to Divi's Laboratories Limited in 1994 to signal its intent to enter the API and intermediates manufacturing industry.[13] Following this, the company established its first Manufacturing facility in 1995 at Choutuppal, Telangana.[1] In 2002, the company's second manufacturing facility commenced operations at Chippada near Visakhapatnam.[1]

The company went public with its initial public offering (IPO) on 17 February 2003.[14][13] In 2010, the company established a research centre in Hyderabad.[1]

Products and services

Active pharmaceutical ingredients (APIs) and intermediates

Divi's Laboratories has between 60 and 85% global market share in generic naproxen, dextromethorphan and gabapentin APIs.[15] The company currently has between 20 and 30% global market share in pregabalin and methylamine APIs.[15] The company's API production is backwards integrated.[16]

Custom synthesis

Divi's Laboratories custom synthesis division provides contract development and manufacturing (CDMO) services and contract research and manufacturing services (CRAMS).[16] The company's clients include 6 of the top 10 largest multinational pharmaceutical companies.[17]

Nutraceuticals

Divi's Nutraceuticals is a subsidiary of Divi's Laboratories, and manufacturers and supplies over 80 forms of carotenoids and vitamins.[10] Divi's Nutraceuticals was founded in 2006 as a subsidiary of Divi's Laboratories.[10]

Facilities

The company has three manufacturing facilities and three R&D centres across India:[1]

Manufacturing

References

  1. ^ a b c d e f g h i j Laboratories, Divi's. "Annual Report" (PDF). divislabs.com. Archived (PDF) from the original on 18 October 2020.
  2. ^ a b "Divi's Laboratories Ltd Company profile". Bloomberg L.P. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  3. ^ "Latest Shareholding Pattern - Divi's Laboratories Ltd". trendlyne.com. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  4. ^ Laboratories, Divi's. "Subsidiary Financials" (PDF). divislabs.com. Archived (PDF) from the original on 18 October 2020.
  5. ^ "Company Profile-DIVIS LAB". Dynamic Levels. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  6. ^ "Company Profile for Divi's Laboratories Ltd". Reuters. Archived from the original on 18 October 2017. Retrieved 15 September 2020.
  7. ^ "DIVI'S LABORATORIES LIMITED - Company, directors and contact details | Zauba Corp". www.zaubacorp.com. Archived from the original on 18 October 2020. Retrieved 15 September 2020.
  8. ^ "Top API Manufacturing Company In Hyderabad, India & World | DivisLabs". Divis Laboratories World’s largest API manufacturing facility. Archived from the original on 12 August 2020. Retrieved 15 September 2020.
  9. ^ Bradstreet, Dun. "Divi's Laboratories company profile". dnb.com. Archived from the original on 18 October 2020.
  10. ^ a b c Divis Nutraceuticals (14 September 2021). "Press Release: Divi's Nutraceuticals launches CaroNat for natural food and beverage coloration". Divi's Nutraceuticals. Retrieved 27 July 2022.
  11. ^ "Top Pharmaceuticals & Drugs Stocks in India by Market Capitalisation". www.moneycontrol.com. Archived from the original on 13 January 2023. Retrieved 15 February 2023.
  12. ^ "India's 100 Richest". India’s 100 Richest. 9 October 2024.
  13. ^ a b "Divis Laboratories > Company History > Pharmaceuticals > Company History of Divis Laboratories - BSE: 532488, NSE: DIVISLAB". moneycontrol.com. Archived from the original on 6 June 2020. Retrieved 17 September 2020.
  14. ^ "Divis Labs Fixes Rs 130 Per Share As Floor Price For IPO". The Financial Express. 11 February 2003. Archived from the original on 17 March 2018. Retrieved 18 September 2020.
  15. ^ a b Khandekar, Siddhant; Shah, Mitesh; Agarwal, Sudarshan (30 May 2021). "Divi's Laboratories (DIVLAB)" (PDF). ICICI Direct. p. 1. Archived (PDF) from the original on 12 October 2022. Retrieved 16 May 2022.
  16. ^ a b Sonavane, Ravindra N. (10 August 2020). "Divi's Labs beats drugmakers to become India's 2nd most valuable pharma company". mint. Archived from the original on 15 August 2020. Retrieved 16 May 2022.
  17. ^ Jauhari, Ujjval (8 February 2021). "Divi's Labs' Dec quarter show is strong but stock remains pricey". mint. Archived from the original on 6 April 2023. Retrieved 16 May 2022.
Kembali kehalaman sebelumnya